Drugs that contain Calcipotriene
1. Dovonex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5763426 | LEO PHARM | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
| USRE39706 | LEO PHARM | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
Market Authorisation Date: 03 March, 1997
Treatment: NA
Dosage: SOLUTION;TOPICAL
How can I launch a generic of DOVONEX before it's drug patent expiration?
More Information on Dosage
DOVONEX family patents
2. Dovonex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5763426 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
| USRE39706 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
Market Authorisation Date: 22 July, 1996
Treatment: NA
Dosage: CREAM;TOPICAL
How can I launch a generic of DOVONEX before it's drug patent expiration?
More Information on Dosage
DOVONEX family patents
3. Sorilux patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8269128 | MAYNE PHARMA | Vacuum switch tube |
May, 2026
(2 years from now) | |
| US8629128 | MAYNE PHARMA | Vitamin formulation |
May, 2026
(2 years from now) | |
| US8263580 | MAYNE PHARMA | Vitamin formulation |
May, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 05, 2022 |
| New Dosage Form(NDF) | Oct 06, 2013 |
| New Indication(I-657) | Sep 27, 2015 |
Market Authorisation Date: 06 October, 2010
Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older
Dosage: AEROSOL, FOAM;TOPICAL
More Information on Dosage
SORILUX family patents